Can your typing patterns reveal if you have Alzheimer’s?The neuroQWERTY technology can analyse people’s typing for signs of motor conditions like Parkinson’s disease – and now Share XCan your typing patterns reveal if you have Alzheimer’s?https://pharmaphorum.com/views-and-analysis/can-your-typing-patterns-reveal-if-you-have-alzheimers/
Acadia puts blame on FDA as Nuplazid rejected for dementiaAcadia Pharmaceuticals is butting heads with US regulators again, this time over the FDA’s decision to reject its Share XAcadia puts blame on FDA as Nuplazid rejected for dementiahttps://pharmaphorum.com/news/acadia-blame-fda-nuplazid-rejected-dementia/
Eisai forges CNS alliance with UK’s Wren TherapeuticsJapanese drugmaker Eisai has teamed up with UK biotech Wren Therapeutics on an R&D programme seeking drugs for Share XEisai forges CNS alliance with UK’s Wren Therapeuticshttps://pharmaphorum.com/news/eisai-forges-cns-alliance-with-uks-wren-therapeutics/
Pain-detecting tool for dementia patients rolls out in UKA smartphone-based app that uses facial analysis technology to spot chronic pain in people with dementia, called PainChek, Share XPain-detecting tool for dementia patients rolls out in UKhttps://pharmaphorum.com/news/pain-detecting-tool-for-dementia-patients-launches-in-uk/
Four ways AI and machine learning will transform healthcare in 2020From AI assisted robotic surgery to clinical diagnosis, image analysis and administrative tasks, the use of artificial intelligence Share XFour ways AI and machine learning will transform healthcare in 2020https://pharmaphorum.com/digital/four-ways-ai-and-machine-learning-will-transform-healthcare-in-2020/
Alkermes bolts on Rodin Therapeutics to bulk up thin pipelineAlkermes has agreed a $950 million deal to acquire Rodin Therapeutics, a US biotech developing drugs for neurodegenerative Share XAlkermes bolts on Rodin Therapeutics to bulk up thin pipelinehttps://pharmaphorum.com/news/alkermes-bolts-on-rodin-therapeutics-to-bulk-up-thin-pipeline/
Searching for new hope in Alzheimer’sFor the best part of two decades, it seemed as if pharma hit a brick wall as it Share XSearching for new hope in Alzheimer’shttps://pharmaphorum.com/r-d/views-analysis-r-d/searching-for-new-hope-in-alzheimers/
Combating chronic diseases through technology and collaborationBy 2050, 2.1bn people globally will be aged 60 or over. That’s more than double the 962m recorded in 2017. This lengthening of life is closely Share XCombating chronic diseases through technology and collaborationhttps://pharmaphorum.com/digital/combating-chronic-diseases-through-technology-and-collaboration/
The challenges of measuring dementiaOxford Brain Diagnostic’s Dr Steven Chance explains the importance of early detection of dementia for treatment and research, Share XThe challenges of measuring dementiahttps://pharmaphorum.com/views-and-analysis/the-challenges-of-measuring-dementia/
